Published in Health Qual Life Outcomes on July 28, 2017
EuroQol--a new facility for the measurement of health-related quality of life. Health Policy (1990) 59.70
Modeling valuations for EuroQol health states. Med Care (1997) 21.66
Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol (2012) 4.52
Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) (2006) 3.73
A review of studies mapping (or cross walking) non-preference based measures of health to generic preference-based measures. Eur J Health Econ (2009) 2.91
State-transition modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--3. Value Health (2012) 1.90
Evaluating psoriasis with Psoriasis Area and Severity Index, Psoriasis Global Assessment, and Lattice System Physician's Global Assessment. J Am Acad Dermatol (2004) 1.82
Whither trial-based economic evaluation for health care decision making? Health Econ (2006) 1.73
Epidemiological aspects of rheumatoid arthritis: the sex ratio. Ann N Y Acad Sci (2006) 1.43
Quantifying the harmful effect of psoriasis on health-related quality of life. J Am Acad Dermatol (2002) 1.37
Swedish experience-based value sets for EQ-5D health states. Qual Life Res (2013) 1.33
Review of 103 Swedish Healthcare Quality Registries. J Intern Med (2014) 1.21
The higher proportion of men with psoriasis treated with biologics may be explained by more severe disease in men. PLoS One (2013) 1.04
Methodological aspects in the assessment of treatment effects in observational health outcomes studies. Appl Health Econ Health Policy (2006) 0.99
PsoReg--the Swedish registry for systemic psoriasis treatment. The registry's design and objectives. Dermatology (2007) 0.90
Analysis of three outcome measures in moderate to severe psoriasis: a registry-based study of 2450 patients. Br J Dermatol (2012) 0.90
Using Linked Electronic Health Records to Estimate Healthcare Costs: Key Challenges and Opportunities. Pharmacoeconomics (2016) 0.90
Exploring the relationship between EQ-5D, DLQI and PASI, and mapping EQ-5D utilities: a cross-sectional study in psoriasis from Hungary. Eur J Health Econ (2014) 0.88